• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Crisaborole Ointment Leads to Significant, Consistent Improvements in AD

Article

In a cohort of Chinese and Japanese pediatric patients, researchers deemed the topical treatment both safe and effective.

Crisaborole ointment 2% was both safe and effective in treating mild-to-moderate cases of atopic dermatitis in a cohort of Chinese and Japanese pediatric patients, according to a poster presented at the Revolutionizing Atopic Dermatitis conference in Washington, DC.1

Aleksej/AdobeStock
Aleksej/AdobeStock

Researchers conducted a post-hoc analysis of a previous phase 3 study in order to determine and analyze the safety and efficacy of crisaborole in a cohort of pediatric patients with the condition across different age subgroups. They cited prior research establishing the safety and efficacy of crisaborole; however, they noted that the effects of the treatment on pediatric patients have not been fully, separately investigated.

Additionally, they cited research demonstrating potential differences in disease course based on ethnicity or race, further noting that atopic dermatitis has a higher disease prevalence in Asian patients than in white patients.

The study being analyzed, CrisADe CLEAR, was multicenter, randomized, double-blind, and vehicle-controlled in nature. Chinese and Japanese patients ages 2 and older had mild-to-moderate atopic dermatitis. All patients were evaluated using the Investigator’s Static Global Assessment (ISGA) and had received a score of 2 or 3. They were also required to have an affected body surface area of 5% or greater, excluding the scalp, for inclusion in the study.

In the study, they underwent a screening period, treatment period, and follow-up period, which lasted 60 days in total. During the treatment period, 260 patients were randomly assigned to receive topical crisaborole ointment 2% on a twice-daily basis. 131 patients were assigned to the vehicle-control group, again receiving the treatment twice per day. This treatment pattern remained consistent for the 28-day treatment period.

During the post-hocanalysis, researchers examined age groups from the CrisADe CLEAR study and stratified patients into 3 separate age groups: 2 to 6 years, 7 to 11 years, and 12 to 17 years.

“Across all age subgroups, patients treated with crisaborole had a greater reduction in the percent change from baseline in EASI total score at day 29 compared to those who received vehicle," study authors wrote. “Patients aged 2-6 years had the largest relative reduction in percent change from baseline in EASI total score at day 29 when comparing crisaboroleversus vehicle-treated patients.”

Furthermore, researchers found that patients ages 2 to 6 and 12 to 17 had higher rates of ISGA improvement when treated with crisaborole as opposed to the vehicle, though all age subgroups experienced higher rates of treatment effectiveness and success when treated with the crisaborole ointment as opposed to their vehicle group counterparts. They also experienced an overall greater reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) score by week 4.

Treatment-emergent adverse events were mostly mild in nature, and most frequently involved application site pain, atopic dermatitis, folliculitis, or application site discoloration.

“Patients treated with crisaborole in each age subgroup had consistent, comparable improvement in all primary and key secondary efficacy endpoints,” study authors wrote. “Crisaborole was well tolerated in all age subgroups, with no new safety signals identified.”

Reference

  1. Zhang J, Ma L, Wang S, Li P, et al. Efficacy and safety of crisaborole ointment, 2%, in Chinese and Japanese patients aged 2-17 years with mild-to-moderate atopic dermatitis.Poster presented at: 2023 Revolutionizing Atopic Dermatitis Conference; April 29-May 1, 2023; Washington, DC. https://djbpnesxepydt.cloudfront.net/radv/April2023/April-2023-Posters/434_Poster_CLEAR_Ped-Subgroup-Analysis_Post-Hoc_Zhang-et-al_1682462290503.pdf

Related Videos
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Video 3 - featuring 2 panelists in, "Navigating Treatment Challenges: Addressing Negative Responses and Determining the Next Course of Action "
Lawrence Eichenfield, MD, an expert on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Video 2 - "Optimizing Long-Term Care: Physician Insights on Secondary Dermatitis Management" - 2 KOLs in this video.
Video 2 - "Real-World Clinical Experience With Ruxolitinib Cream Monotherapy to Manage Atopic Dermatitis"
Video 1 - "Creating a Connection: First Appointment Insights and Critical Inquiries Providers Should Make"
Video 1 - "Insights for Clinicians: Leveraging Real-World Data for Informed Practice"
© 2024 MJH Life Sciences

All rights reserved.